Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 901 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Ventana HER2 Dual ISH Assay, A New Diagnostic Tool From Roche,... June 7, 2019 “I feel extremely proud when I look at what we’ve achieved”: ScottishPower’s Andrew... June 3, 2021 FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma April 27, 2022 Should People Over Age 75 Be Screened for Colorectal Cancer? June 15, 2021 Load more HOT NEWS Young Mom With Metastatic Breast Cancer Travels To Mexico For Alternative... Inspiring the next generation of cancer researchers Haematologic Toxicity Not Increased with Immunochemotherapy Combinations Over Chemotherapy Treatment for... Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast
